Dichlorphenamide: A Review in Primary Periodic Paralyses
- 470 Downloads
Oral dichlorphenamide (Keveyis™) is a carbonic anhydrase inhibitor that is approved in the USA for the treatment of primary hyperkalaemic and hypokalaemic periodic paralyses and related variants. The efficacy and safety of dichlorphenamide in patients with primary periodic paralyses have been evaluated in four 9-week, randomized, double-blind, placebo-controlled, phase III trials [two parallel-group trials (HOP and HYP) and two crossover trials]. In two trials in patients with hypokalaemic periodic paralysis, dichlorphenamide was associated with a significantly (eightfold) lower paralytic attack rate and fewer patients with acute intolerable worsening compared with placebo. In two trials in patients with hyperkalaemic periodic paralysis, the attack rate was lower with dichlorphenamide than placebo, with this comparison reaching statistical significance in one trial (crossover) but not the other (HYP), although the attack rate was approximately fivefold lower with dichlorphenamide than placebo in the HYP trial. In 52-week, open-label extensions of the HOP and HYP trials, dichlorphenamide provided sustained efficacy in patients with hypokalaemic or hyperkalaemic periodic paralysis. Dichlorphenamide was generally well tolerated in all four phase III trials and during the extension trials; the most common adverse events were paraesthesia, cognitive disorders and dysgeusia. As the first agent to be approved in the USA for this indication, dichlorphenamide is a valuable treatment option for patients with primary hyperkalaemic or hypokalaemic periodic paralysis.
KeywordsAttack Rate Crossover Trial Periodic Paralysis Hypokalemic Periodic Paralysis Hyperkalemic Periodic Paralysis
During the peer review process, the manufacturer of dichlorphenamide was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
Sarah Greig is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 3.Statland JM, Barohn RJ. Muscle channelopathies: the nondystrophic myotonias and periodic paralyses. Continuum. 2013;19(6 Muscle Disease):1598–614.Google Scholar
- 4.Taro Pharmaceuticals USA Inc. Keveyis™ (dichlorphenamide) tablets, for oral use: US prescribing information. 2015. http://www.fda.gov. Accessed 25 Feb 2016.
- 5.Taro Pharmaceuticals Industries Ltd. FDA approves Keveyis (dichlorphenamide) for primary hyperkalemic and hypokalemic periodic paralysis [media release]. 10 Aug 2015. http://www.drugs.com/newdrugs.
- 6.US Food and Drug Administration. Determination that Daranide (dichlorphenamide) tablets, 50 milligrams, were not withdrawn from sale for reasons of safety or effectiveness. Fed Regist. 2007;72(150):43645.Google Scholar
- 8.Tricarico D, Mele A, Calzolaro S, et al. Emerging role of calcium-activated potassium channel in the regulation of cell viability following potassium ions challenge in HEK293 cells and pharmacological modulation. PLoS One. 2013;8(7):[article no. e69551].Google Scholar